Managers

Endotronix inks $45 mln Series D

Lisle, Illinois-based Endotronix Inc, a digital health focused on advancing the treatment of heart failure, has raised $45 million in Series D funding. LSP led the round with participation from other investors that included Aperture Venture Partners, BioVentures Investors, Lumira Ventures, OSF Ventures, Seroba Life Sciences, SV Health Investors and Wanxiang Healthcare Investments.

Fintech investors look globally for deals

Goldman Sachs emerges as lead buyer on innovative NEA secondary deal

Seven Peaks Ventures wraps up second fund at $28 mln

Seven Peaks Ventures has closed its second fund at $28 million. The limited partners of Seven Peaks Venture II includes the State of Oregon, the OSU Foundation and family offices. The Bend, Oregon-based venture firm is focused on tech companies.

Ribbit Capital targets $420 mln for fifth fund

Ribbit Capital is seeking to raise $420 million for its fifth fund, according to an SEC filing. The Palo Alto, California-based venture firm is focused on the fintech sector.

Coda Biotherapeutics picks up $19 mln Series A

South San Francisco-based Coda Biotherapeutics Inc, a developer of a chemogenetic gene therapy platform for the treatment of intractable diseases, has raised $19 million in Series A financing. MPM Capital and Versant Ventures were the lead investors.

System1 Biosciences procures $25 mln Series A

System1 Biosciences Inc, a San Francisco-based neurotherapeutics company, has closed $25 million in Series A financing. CRV and Pfizer Ventures led the round with participation from Alexandria Venture Investments, Dolby Family Ventures, Longevity Fund, Riot Ventures, Kinled Holding, Wilmot Ventures, Webb Investment Network, Liquid 2 Ventures and Boom Capital.

Biotech firm Atreca rakes in $125 mln Series C

Redwood City, California-based Atreca Inc, a biotechnology company, has secured $125 million in Series C financing. The investors included Wellington Management Company LLC, Cormorant Asset Management, Aisling Capital, Boxer Capital of the Tavistock Group, EcoR1 Capital, Redmile Group, Samsara BioCapital and funds managed by Tekla Capital Management.

Boehringer Ingelheim acquires ViraTherapeutics for $245 mln

Boehringer Ingelheim has acquired Austria-based ViraTherapeutics, a developer of virus-based immunotherapeutics for the treatment of cancer, for $245 million. ViraTherapeutics was a portfolio company of EMBL Ventures.

VC-backed Travecta taps Hicks as chief business officer

Travecta Therapeutics, an emerging biotech company, has appointed Douglas C. Hicks as chief business officer. Previously, Hicks worked at iBio Inc where he served as senior vice president of business development and strategy. Based in Philadelphia and Singapore, Travecta is backed by TKS1, a healthcare and life science-focused venture capital fund formed by the partnership between SPRIM Ventures and Tikehau Capital.